Thalidomide, stanozolol combined with prednisone for improvement of the related hematologic adverse reactions of ruxolitinib in patients with myelofibrosis
10.3760/cma.j.issn.1009-9921.2018.05.003
- VernacularTitle: 沙利度胺、司坦唑醇联合泼尼松用于改善骨髓纤维化患者芦可替尼治疗相关血液学不良反应
- Author:
Minghui DUAN
1
;
Yan ZHANG
;
Daobin ZHOU
Author Information
1. Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
- Publication Type:Journal Article
- Keywords:
Myelofibrosis;
Drug therapy, combination;
Thalidomide;
Stanozolol;
Prednisone;
Ruxolitinib
- From:
Journal of Leukemia & Lymphoma
2018;27(5):268-271
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the clinical effects and safety of combination treatment of thalidomide, stanozolol, and prednisone (TSP regimen) in patients with myelofibrosis (MF) who experienced hematological adverse reactions during ruxolitinib treatment.
Methods:Ten MF patients with anemia or thrombocytopenia during ruxolitinib treatment from January 2016 to July 2017 in Peking Union Medical College Hospital were retrospectively analyzed. All patients were treated with a combination of low dose of thalidomide (around 75 mg/d), stanozolol (2 mg/time, 3 times per day), and low dose of prednisone (0.5 mg·kg-1·d-1). The hematological response and safety were assessed.
Results:There were 9 cases of anemia and 7 cases of thrombocytopenia during ruxolitinib treatment. After TSP regimen treatment, there were 5 cases of hemoglobin response including 1 case of complete remission (CR). There were 4 cases of platelet response and all achieved CR. Totally, the hematological overall response was seen in 7 cases. The median time from taking medicine to getting response was 27 d (13-89 d). 3 patients lost efficacy, while the median duration of response didn't reach (28-207 d).
Conclusion:TSP regimen can improve anemia or thrombocytopenia during ruxolitinib treatment in patients with MF.
